Skip to main content

Table 2 Clinicopathologic correlations of PD-L1 expression, PIK3CA mutation, and MSI/dMMR status

From: Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma

  

PD-L1 expression

P

PIK3CA

P

MSI/dMMR

P

Total

Positive

Negative

 

MT

WT

 

Positive

Negative

 

N = 64 (%)

n = 23 (35.9%)

n = 41 (64.1%)

 

n = 8 (12.5%)

n = 56 (87.5%)

 

n = 11 (17.2%)

n = 53 (82.8%)

 

Sex

   

0.545

  

0.019

  

1.000

 Male

60 (93.8)

21 (91.3)

39 (95.1)

 

6 (75.0)

54 (96.4)

 

11 (100)

49 (92.5)

 

 Female

4 (6.2)

2 (8.7)

2 (4.9)

 

2 (25.0)

2 (3.6)

 

0 (0.0)

4 (7.5)

 

Age (years)

   

0.291

  

0.043

  

0.039

  ≤ 60

26 (40.6)

7 (30.4)

19 (46.3)

 

6 (75.0)

20 (35.7)

 

8 (72.7)

18 (34.0)

 

  > 60

38 (59.4)

16 (69.6)

22 (53.7)

 

2 (25.0)

36 (64.3)

 

3 (27.3)

35 (66.0)

 

Smoking

   

0.048

  

0.850

  

0.322

 Light

34 (53.1)

16 (69.6)

18 (4.9)

 

4 (50.0)

30 (53.6)

 

4 (36.4)

30 (56.6)

 

 Heavy

30 (46.9)

7 (30.4)

23 (56.1)

 

4 (50.0)

26 (46.4)

 

7 (63.6)

23 (43.4)

 

Alcohol

   

0.728

  

0.564

  

0.176

 Light

26 (40.6)

10 (43.5)

16 (39.0)

 

4 (50.0)

22 (39.3)

 

2 (18.2)

24 (45.3)

 

 Heavy

38 (59.4)

13 (56.5)

25 (61.0)

 

4 (50.0)

34 (60.7)

 

9 (81.8)

29 (54.7)

 

Location

   

0.216

  

0.179

  

1.000

 Upper/Middle

45 (70.3)

14 (60.9)

31 (48.4)

 

4 (50.0)

41 (73.2)

 

8 (72.7)

37 (69.8)

 

 Lower

19 (29.7)

9 (39.1)

10 (15.6)

 

4 (50.0)

15 (26.8)

 

3 (27.3)

16 (30.2)

 

Differentiation

   

0.291

  

0.253

  

0.039

 WD

26 (40.6)

7 (30.4)

19 (46.3)

 

5 (62.5)

21 (37.5)

 

8 (72.7)

18 (34.0)

 

 MD/PD

38 (59.4)

16 (69.6)

22 (53.7)

 

3 (37.5)

35 (62.5)

 

3 (27.3)

35 (66.0)

 

T category

   

0.622

  

0.282

  

0.428

 T1-T2

36 (56.2)

12 (52.2)

24 (58.5)

 

3 (37.5)

33 (58.9)

 

5 (45.5)

31 (58.5)

 

 T3-T4

28 (43.8)

11 (47.8)

17 (41.5)

 

5 (62.5)

23 (41.1)

 

6 (54.5)

22 (41.5)

 

N category

   

0.282

  

0.498

  

0.247

 N0

39 (60.9)

12 (52.2)

27 (65.9)

 

4 (50.0)

35 (62.5)

 

5 (45.5)

34 (64.2)

 

 N1–3

25 (39.1)

11 (47.8)

14 (34.1)

 

4 (50.0)

21 (37.5)

 

6 (54.5)

19 (35.8)

 

AJCC stage

   

0.459

  

0.435

  

0.199

 I-II

40 (62.5)

13 (56.5)

27 (65.9)

 

4 (50.0)

36 (64.3)

 

5 (45.5)

35 (66.0)

 

 III-IV

24 (37.5)

10 (43.5)

14 (34.1)

 

4 (50.0)

20 (35.7)

 

6 (54.5)

18 (34.0)

 

LI

   

0.291

  

0.456

  

1.000

 Absent

26 (40.6)

7 (30.4)

19 (46.3)

 

2 (25.0)

24 (42.9)

 

4 (36.4)

22 (41.5)

 

 Present

38 (59.4)

16 (69.6)

22 (53.7)

 

6 (75.0)

32 (57.1)

 

7 (63.6)

31 (58.5)

 

VI

   

0.648

  

0.683

  

1.000

 Absent

44 (68.8)

15 (65.2)

29 (70.7)

 

5 (62.5)

39 (69.6)

 

8 (72.7)

36 (67.9)

 

 Present

20 (31.2)

8 (34.8)

12 (29.3)

 

3 (37.5)

17 (30.4)

 

3 (27.3)

17 (32.1)

 

PI

   

0.755

  

0.196

  

1.000

 Absent

51 (79.7)

19 (82.6)

32 (78.0)

 

5 (62.5)

46 (82.1)

 

9 (81.8)

42 (79.2)

 

 Present

13 (20.3)

4 (17.4)

9 (22.0)

 

3 (37.5)

10 (17.9)

 

2 (18.2)

11 (20.8)

 

Skip lesion

   

0.345

  

0.673

  

0.431

 Absent

50 (78.1)

20 (87.0)

30 (73.2)

 

7 (87.5)

43 (76.8)

 

10 (90.9)

40 (75.5)

 

 Present

14 (21.9)

3 (13.0)

11 (26.8)

 

1 (12.5)

13 (23.2)

 

1 (0.1)

13 (24.5)

 

Dysplasia

   

0.610

  

0.060

  

0.058

 Absent

36 (56.2)

14 (60.9)

22 (53.7)

 

7 (87.5)

29 (51.8)

 

9 (81.8)

27 (50.9)

 

 Present

28 (43.8)

9 (39.1)

19 (46.3)

 

1 (12.5)

27 (48.2)

 

2 (18.2)

26 (49.1)

 

TIL density

   

0.170

  

0.320

  

0.395

 Low

22 (34.4)

5 (21.7)

17 (41.5)

 

4 (50.0)

18 (32.1)

 

5 (45.5)

17 (32.1)

 

 High

42 (65.6)

18 (78.3)

24 (58.5)

 

4 (50.0)

38 (67.9)

 

6 (54.5)

36 (67.9)

 

HPV

   

1.000

  

1.000

  

1.000

 Negative

63 (98.4)

23 (100)

40 (97.6)

 

8 (100)

55 (98.2)

 

11 (100)

52 (98.1)

 

 Positive

1 (1.6)

0 (0.0)

1 (2.4)

 

0 (0.0)

1 (1.8)

 

0 (0.0)

1 (1.9)

 

MSI/MMR

   

0.732

  

0.531

  

–

 MSS/pMMR

53 (82.8)

20 (87.0)

33 (80.5)

 

6 (75.0)

47 (83.9)

 

–

–

 

 MSI/dMMR

11 (17.2)

3 (13.0)

8 (19.5)

 

2 (25.0)

9 (16.1)

 

–

–

 

PIK3CA status

   

0.700

      

 Wildtype

56 (87.5)

21 (91.3)

35 (85.4)

 

–

–

 

–

–

 

 Mutated

8 (12.5)

2 (8.7)

6 (14.6)

 

–

–

 

–

–

 
  1. ESCC esophageal squamous cell carcinoma, PD-L1 programmed death ligand-1, MT mutated, WT wild type, MSI microsatellite instability, pMMR patent mismatch repair, dMMR deficient mismatch repair, AJCC Amedican Joint Committee on Cancer 8th edition, WD well-differentiation, MD moderately-differentiation, PD poorly-differentiation, LI lymphatic invasion, VI vascular invasion, PI perineural invasion, TIL tumor-infiltrating lymphocyte, HPV human papillomavirus
Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us